Advances in acute myeloid leukemia
LF Newell, RJ Cook - Bmj, 2021 - bmj.com
Acute myeloid leukemia (AML) is an uncommon but potentially catastrophic diagnosis with
historically high mortality rates. The standard of care treatment remained unchanged for …
historically high mortality rates. The standard of care treatment remained unchanged for …
Towards precision medicine for AML
With rapid advances in sequencing technologies, tremendous progress has been made in
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
understanding the molecular pathogenesis of acute myeloid leukaemia (AML), thus …
[HTML][HTML] Eprenetapopt plus azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des …
T Cluzeau, M Sebert, R Rahmé… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE TP53-mutated (TP53m) myelodysplastic syndromes (MDS) and acute myeloid
leukemia (AML) have very poor outcome irrespective of the treatment received, including …
leukemia (AML) have very poor outcome irrespective of the treatment received, including …
Applying high-dimensional single-cell technologies to the analysis of cancer immunotherapy
SH Gohil, JB Iorgulescu, DA Braun, DB Keskin… - Nature Reviews …, 2021 - nature.com
Advances in molecular biology, microfluidics and bioinformatics have empowered the study
of thousands or even millions of individual cells from malignant tumours at the single-cell …
of thousands or even millions of individual cells from malignant tumours at the single-cell …
Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based …
J Stomper, JC Rotondo, G Greve, M Lübbert - Leukemia, 2021 - nature.com
Aberrant DNA methylation plays a pivotal role in tumor development and progression. DNA
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …
hypomethylating agents (HMA) constitute a class of drugs which are able to reverse DNA …
Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia
EM Cherry, D Abbott, M Amaya, C McMahon… - Blood …, 2021 - ashpublications.org
Venetoclax (ven) plus azacitidine (aza) is the standard of care for patients with newly
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …
diagnosed acute myeloid leukemia (AML) who are not candidates for intensive …
Emerging agents and regimens for AML
H Liu - Journal of hematology & oncology, 2021 - Springer
Until recently, acute myeloid leukemia (AML) patients used to have limited treatment options,
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …
depending solely on cytarabine+ anthracycline (7+ 3) intensive chemotherapy and …
[HTML][HTML] Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia
CD DiNardo, AS Stein, EM Stein, AT Fathi… - Journal of Clinical …, 2021 - ncbi.nlm.nih.gov
PURPOSE Ivosidenib is an oral inhibitor of the mutant isocitrate dehydrogenase 1 (IDH1)
enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML) …
enzyme, approved for treatment of IDH1-mutant (mIDH1) acute myeloid leukemia (AML) …
Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML
Abstract Azacitidine+ venetoclax, decitabine+ venetoclax, and low-dose cytarabine+
venetoclax are now standard treatments for newly diagnosed older or unfit patients with …
venetoclax are now standard treatments for newly diagnosed older or unfit patients with …
Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclax
Background TP53 mutation (TP53mut) confers an adverse prognosis in acute myeloid
leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older …
leukemia (AML). Venetoclax with hypomethylating agents is a current standard for older …